Actively Recruiting
A Registry-Based Cohort Study on the Clinical Outcomes of Spinal Cord Glioma Resection Via the Dorsolateral Sulcus Approach
Led by Beijing Tiantan Hospital · Updated on 2025-07-23
100
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Spinal cord gliomas are the most common type of primary intramedullary malignant tumors, with a low incidence and a peak onset age of approximately 35 years. They are slightly more prevalent in males than females. Clinical manifestations vary depending on tumor characteristics and location, typically presenting with axial pain and displaying a tendency for unilateral, infiltrative growth. Prognosis is generally poor, and effective treatment options are limited aside from surgical resection. Common surgical approaches for intramedullary tumor removal include the posterior median sulcus approach, the dorsolateral sulcus approach, and surface entry techniques. Preliminary clinical observations suggest that the dorsolateral sulcus approach may offer superior preservation of neurological function and quality of life. However, due to limited research evaluating the safety and efficacy of different surgical routes, the traditional posterior median sulcus approach remains widely used. This single-center, registry-based cohort study aims to compare the outcomes of spinal cord glioma resection via the dorsolateral sulcus approach versus the posterior median sulcus approach. Patients with laterally located tumors undergoing surgical treatment, classified according to the 2021 WHO criteria, will be included. Neurological function scores and quality-of-life assessments will be used to evaluate prognosis and survival, in order to determine the optimal surgical approach for spinal cord glioma resection.
CONDITIONS
Official Title
A Registry-Based Cohort Study on the Clinical Outcomes of Spinal Cord Glioma Resection Via the Dorsolateral Sulcus Approach
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 3 and 75 years
- Undergoing surgical removal of a spinal cord tumor
- Histopathological confirmation of spinal cord glioma
- Complete clinical data available and willingness to participate in follow-up
- Informed consent from patient or legal guardian
You will not qualify if you...
- Age under 3 years or over 75 years
- Radiotherapy, chemotherapy, or anti-tumor biological therapy within 1 month before enrollment
- Immunotherapy within 3 months before enrollment
- Participation in other clinical trials within 3 months before enrollment
- History of severe allergies or allergy-prone condition
- Pregnant or breastfeeding women, or those not using contraception if of childbearing potential
- Presence of severe medical conditions or uncontrolled infections
- History of drug abuse, chronic alcoholism, or HIV infection
- Uncontrolled seizures or psychiatric disorders causing loss of self-control
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100070
Actively Recruiting
Research Team
W
Wang Yongzhi Wang, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here